Abbott and Biocurex enter into agreement for RECAF(TM) cancer technology
"Because many cancer deaths may be prevented with early screening and treatment, it's important to develop new cancer tests that could more effectively target a specific type of cancer. Preliminary studies indicate that RECAF may provide good clinical sensitivity and specificity as a tumor marker," said William Brown, Ph.D., vice president, Diagnostic Assays and Systems Development, Abbott.
Under terms of the agreement, Abbott obtains worldwide, semi-exclusive rights to commercialize products using BioCurex's RECAF technology. The agreement includes payment to BioCurex of up-front fees, product development milestones and royalties on any product sales. Other terms of the agreement were not disclosed.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.